In 2004, the European nonvascular stenting products market was valued at approximately $81.2 million.  Over the forecast period covered by this report, sales are expected to increase at a compound annual rate of 5.1%, reaching approximately $114.4 million in the year 2011.  Market drivers include the aging of the population, improved screening and detection of diseases, technological advances, and a shift from lower-priced plastic stents to higher-priced metal stents.

This report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the European nonvascular stents market.

Topics discussed in this report include overviews of European healthcare systems as well as nonvascular diseases and treatments, bile duct stenting, esophageal stenting, tracheobronchial stenting, and urethral and prostatic stenting.  Countries covered by this report include France; Germany; Italy; Spain; and the United Kingdom; the Benelux countries of Belgium, the Netherlands, and Luxembourg; and the Nordic countries of Denmark, Finland, Iceland, Norway, and Sweden.

TABLE OF CONTENTS AND LIST OF EXHIBITS

EXECUTIVE SUMMARY

i.   Methodology Statement

ii.   European Nonvascular Stents Market

a.  Bile Duct Stents

b.  Esophageal Stents

c.  Tracheobronchial Stents

d.  Urethral/Prostatic Stents

e.  Market Forecast

f.   Market Drivers

g.  Market Limiters

Exhibit ES-1:  Europe, Nonvascular Stents, Market Forecast, 2004-2011

Exhibit ES-2:  Europe, Nonvascular Stents, Market Forecast, by Country, 2004-2011

1. EUROPEAN HEALTHCARE MARKET OVERVIEW

1.1 The European Union

1.1.1 A Common Currency

1.1.2 Regulatory Policies

1.1.3 Reimbursement

1.1.4 Healthcare Spending

1.2 National Profiles

1.2.1 France

1.2.1.1 Healthcare Organization and Reform

1.2.1.2 Hospital Services

1.2.1.3 Medical Device Reimbursement

1.2.2 Germany

1.2.2.1 Healthcare Organization and Reform

1.2.2.2 Hospital Services

1.2.2.3 Medical Device Reimbursement

1.2.3 Italy

1.2.3.1 Healthcare Organization and Reform

1.2.3.2 Hospital Services

1.2.3.3 Medical Device Reimbursement

1.2.4 Spain

1.2.4.1 Healthcare Organization and Reform

1.2.4.2 Hospital Services

1.2.4.3 Medical Device Reimbursement

1.2.5 United Kingdom

1.2.5.1 Healthcare Organization and Reform

1.2.5.2 Hospital Services

1.2.5.3 Medical Device Reimbursement

1.2.6 Benelux Countries

1.2.6.1 Healthcare Organization and Reform

1.2.6.2 Hospital Services

1.2.6.3 Medical Device Reimbursement

1.2.7 Nordic Countries

1.2.7.1 Healthcare Organization and Reform

1.2.7.1.1 Denmark

1.2.7.1.2 Finland

1.2.7.1.3 Iceland

1.2.7.1.4 Norway

1.2.7.1.5 Sweden

1.2.7.2 Hospital Services

1.2.7.2.1 Denmark

1.2.7.2.2 Finland

1.2.7.2.3 Iceland

1.2.7.2.4 Norway

1.2.7.2.5 Sweden

1.2.7.3 Medical Device Reimbursement

1.2.7.3.1 Denmark

1.2.7.3.2 Finland

1.2.7.3.3 Iceland

1.2.7.3.4 Norway

1.2.7.3.5 Sweden

Exhibit 1-1:    European Union, Medical Devices Risk Classification System

Exhibit 1-2:    European Union, Population Statistics Comparison, 1994 and 2004

Exhibit 1-3:    France, Selected National Healthcare Statistics

Exhibit 1-4:    Germany, Selected National Healthcare Statistics

Exhibit 1-5:    Italy, Selected National Healthcare Statistics

Exhibit 1-6:    Spain, Selected National Healthcare Statistics

Exhibit 1-7:    United Kingdom, Selected National Healthcare Statistics

Exhibit 1-8:    Belgium, Selected National Healthcare Statistics

Exhibit 1-9:    Netherlands, Selected National Healthcare Statistics

Exhibit 1-10:  Luxembourg, Selected National Healthcare Statistics

Exhibit 1-11:  Denmark, Selected National Healthcare Statistics

Exhibit 1-12:  Finland, Selected National Healthcare Statistics

Exhibit 1-13:  Iceland, Selected National Healthcare Statistics

Exhibit 1-14:  Norway, Selected National Healthcare Statistics

Exhibit 1-15:  Sweden, Selected National Healthcare Statistics

2. OVERVIEW OF STENTING FOR NONVASCULAR APPLICATATIONS

2.1 Bile Duct Diseases

2.1.1 Benign Biliary Strictures

2.1.2 Malignant Biliary Strictures

2.1.3 Treatment

2.2 Esophageal Diseases

2.2.1 Benign Esophageal Strictures

2.2.2 Malignant Esophageal Strictures

2.2.3 Treatment

2.2.3.1 Nonsurgical Treatment

2.2.3.2 Surgical Treatment

2.3 Renal System Diseases

2.3.1 Benign Urethral and Prostatic Strictures

2.3.2 Malignant Urethral and Prostatic Strictures

2.3.3 Treatment

2.4 Tracheobronchial System Diseases

2.4.1 Benign Tracheobronchial Strictures

2.4.2 Malignant Tracheobronchial Strictures

2.4.3 Treatment

2.4.3.1 Expandable Metal Stents

2.4.3.2 Silicone Stents

3. THE EUROPEAN NONVASCULAR STENTS MARKET

3.1 Market Drivers

3.2 Market Limiters

3.3 Market Analysis

3.3.1 Market Forecast, by Country

3.3.1.1 France

3.3.1.2 Germany

3.3.1.3 Italy

3.3.1.4 Spain

3.3.1.5 United Kingdom

3.3.1.6 Benelux Countries

3.3.1.7 Nordic Countries

3.3.1.8 Rest-of-Europe

3.3.2 Competitive Analysis

3.4 Biliary Duct Stents

3.4.1 Products

3.4.2 Market Analysis

3.4.2.1 Market Forecast, by Country

3.4.2.2 Competitive Analysis

3.5 Esophageal Stents

3.5.1 Products

3.5.2 Market Analysis

3.5.2.1 Market Forecast, by Country

3.5.2.2 Competitive Analysis

3.6 Tracheobronchial Stents

3.6.1 Products

3.6.1.1 Metal Tracheobronchial Stents

3.6.1.2 Silicone Tracheobronchial Stents

3.6.2 Market Analysis

3.6.2.1 Market Forecast, by Country

3.6.2.2 Competitive Analysis

3.7 Urethral and Prostatic Stents

3.7.1 Products

3.7.2 Market Analysis

3.7.2.1 Market Forecast, by Country

3.7.2.2 Competitive Analysis

Exhibit 3-1:    Europe, Nonvascular Stents, Market Forecast, 2004-2011

Exhibit 3-2:    France, Nonvascular Stents, Market Forecast, 2004-2011

Exhibit 3-3:    Germany, Nonvascular Stents, Market Forecast, 2004-2011

Exhibit 3-4:    Italy, Nonvascular Stents, Market Forecast, 2004-2011

Exhibit 3-5:    Spain, Nonvascular Stents, Market Forecast, 2004-2011

Exhibit 3-6:    United Kingdom, Nonvascular Stents, Market Forecast, 2004-2011

Exhibit 3-7:    Benelux Countries, Nonvascular Stents, Market Forecast, 2004-2011

Exhibit 3-8:    Nordic Countries, Nonvascular Stents, Market Forecast, 2004-2011

Exhibit 3-9:    Rest-of-Europe, Nonvascular Stents, Market Forecast, 2004-2011

Exhibit 3-10:  2004, Europe, Nonvascular Stents Market, Share by Supplier

Exhibit 3-11:  2004, France, Nonvascular Stents Market, Share by Supplier

Exhibit 3-12:  2004, Germany, Nonvascular Stents Market, Share by Supplier

Exhibit 3-13:  2004, Italy, Nonvascular Stents Market, Share by Supplier

Exhibit 3-14:  2004, Spain, Nonvascular Stents Market, Share by Supplier

Exhibit 3-15:  2004, United Kingdom, Nonvascular Stents Market, Share by Supplier

Exhibit 3-16:  2004, Benelux Countries, Nonvascular Stents Market, Share by Supplier

Exhibit 3-17:  2004, Nordic Countries, Nonvascular Stents Market, Share by Supplier

Exhibit 3-18:  2004, Rest-of-Europe, Nonvascular Stents Market, Share by Supplier

Exhibit 3-19:  Europe, Biliary Duct Stents, Market Forecast, 2004-2011

Exhibit 3-20:  France, Biliary Duct Stents, Market Forecast, 2004-2011

Exhibit 3-21:  Germany, Biliary Duct Stents, Market Forecast, 2004-2011

Exhibit 3-22:  Italy, Biliary Duct Stents, Market Forecast, 2004-2011

Exhibit 3-23:  Spain, Biliary Duct Stents, Market Forecast, 2004-2011

Exhibit 3-24:  United Kingdom, Biliary Duct Stents, Market Forecast, 2004-2011

Exhibit 3-25:  Benelux Countries, Biliary Duct Stents, Market Forecast, 2004-2011

Exhibit 3-26:  Nordic Countries, Biliary Duct Stents, Market Forecast, 2004-2011

Exhibit 3-27:  Rest-of-Europe, Biliary Duct Stents, Market Forecast, 2004-2011

Exhibit 3-28:  2004, Europe, Biliary Duct Stents Market, Share by Supplier

Exhibit 3-29:  Europe, Esophageal and Nonvascular Stents, Market Forecast, 2004-2011

Exhibit 3-30:  France, Esophageal Stents, Market Forecast, 2004-2011

Exhibit 3-31:  Germany, Esophageal Stents, Market Forecast, 2004-2011

Exhibit 3-32:  Italy, Esophageal Stents, Market Forecast, 2004-2011

Exhibit 3-33:  Spain, Esophageal Stents, Market Forecast, 2004-2011

Exhibit 3-34:  United Kingdom, Esophageal Stents, Market Forecast, 2004-2011

Exhibit 3-35:  Benelux Countries, Esophageal Stents, Market Forecast, 2004-2011

Exhibit 3-36:  Nordic Countries, Esophageal Stents, Market Forecast, 2004-2011

Exhibit 3-37:  Rest-of-Europe, Esophageal Stents, Market Forecast, 2004-2011

Exhibit 3-38:  2004, Europe, Esophageal Stents Market, Share by Supplier

Exhibit 3-39:  Advantages and Disadvantages of Metal and Silicone Tracheobronchial Stents

Exhibit 3-40:  Europe, Tracheobronchial and Nonvascular Stents, Market Forecast, 2004-2011

Exhibit 3-41:  France, Tracheobronchial Stents, Market Forecast, 2004-2011

Exhibit 3-42:  Germany, Tracheobronchial Stents, Market Forecast, 2004-2011

Exhibit 3-43:  Italy, Tracheobronchial Stents, Market Forecast, 2004-2011

Exhibit 3-44:  Spain, Tracheobronchial Stents, Market Forecast, 2004-2011

Exhibit 3-45:  United Kingdom, Tracheobronchial Stents, Market Forecast, 2004-2011

Exhibit 3-46:  Benelux Countries, Tracheobronchial Stents, Market Forecast, 2004-2011

Exhibit 3-47:  Nordic Countries, Tracheobronchial Stents, Market Forecast, 2004-2011

Exhibit 3-48:  Rest-of-Europe, Tracheobronchial Stents, Market Forecast, 2004-2011

Exhibit 3-49:  2004, Europe, Tracheobronchial Stents Market, Share by Supplier

Exhibit 3-50:  Europe, Urethral and Prostatic Stents, Market Forecast, 2004-2011

Exhibit 3-51:  France, Urethral and Prostatic Stents, Market Forecast, 2004-2011

Exhibit 3-52:  Germany, Urethral and Prostatic Stents, Market Forecast, 2004-2011

Exhibit 3-53:  Italy, Urethral and Prostatic Stents, Market Forecast, 2004-2011

Exhibit 3-54:  Spain, Urethral and Prostatic Stents, Market Forecast, 2004-2011

Exhibit 3-55:  United Kingdom, Urethral and Prostatic Stents, Market Forecast, 2004-2011

Exhibit 3-56:  Benelux Countries, Urethral and Prostatic Stents, Market Forecast, 2004-2011

Exhibit 3-57:  Nordic Countries, Urethral and Prostatic Stents, Market Forecast, 2004-2011

Exhibit 3-58:  Rest-of-Europe, Urethral and Prostatic Stents, Market Forecast, 2004-2011

Exhibit 3-59:  2004, Europe, Urethral and Prostatic Stents Market, Share by Supplier

4. COMPETITIVE TECHNOLOGIES

4.1 Endovascular Brachytherapy

4.1.1 Technology

4.1.2 Isotopes

4.1.3 Delivery Systems

4.1.3.1 Gas-Filled Balloons

4.1.3.2 Liquid-Filled Balloons

4.1.3.3 Radioactive Stents

4.1.3.4 Seeds

4.1.3.5 Wires

4.1.4 Advantages and Disadvantages

4.1.5 Clinical Trials

4.2 Photodynamic Therapy

4.2.1 Technology

4.2.2 Products

4.3 Therapeutic Angiogenesis

4.3.1 Technology

4.3.2 Clinical Trials

4.4 Therapeutic Apheresis

4.4.1 Technology

4.4.2 Products

4.5 Statins

4.5.1 Technology

4.5.2 Products

Exhibit 4-1:    2004, Number of Brachytherapy Facilities in Europe

Exhibit 4-2:    2005, Selected Radionuclides for Endovascular Brachytherapy

Exhibit 4-3:    Summary of Clinical Trials for the Study of Endovascular Brachytherapy in Femoropopliteal Restenosis Prevention

Exhibit 4-4:    Growth Factors That Promote Angiogenesis

Exhibit 4-5:    Clinical Trials for the Study of Therapeutic Angiogenesis

Exhibit 4-6:    2005, Comparison of Currently Available Statins

5. COMPANY PROFILES

5.1     Abbott Laboratories

5.2     C.R. Bard, Inc.

5.3     Boston Scientific Corporation

5.4     ConMed Corporation

5.5     Cook Group, Inc.

5.6     Cordis Corporation/Johnson & Johnson

5.7     ELLA-CS

5.8     ENGINEERS & DOCTORS A/S

5.9     Guidant Corporation

5.10    Medtronic, Inc.

5.11    M.I. Tech Co., LTD

5.12    Novatech SA

5.13    Rüsch, Inc./Teleflex, Inc.

APPENDIX:  COMPANY LISTING

Copyright 2005, Medtech Insight, LLC